

23rd Annual Meeting of the Swiss Transplantation Society



January 22-23, 2026

Congress Hotel Seepark
Thun, Switzerland

Congress Organization

Prof. Philipp Dutkowski, President STS
Prof. Nicolas Müller
Chair of the Scientific Committee

Congress Secretariat

Meeting.com Sàrl Congress Organisation
www.meetingcom.ch • info@meetingcom.ch

Online registration on [www.meetingcom.ch/
Conferences & Meetings](http://www.meetingcom.ch/Conferences%20&%20Meetings)



Your partner in transplantation

Every life line
tells a story



Wedding
Birth of the children
Organ failure
Transplantation
Wedding of the children
Birth of the grandchildren

Date of preparation: 05/2019 TX_2019_0005_CH

Welcome letter

Dear Colleagues, Dear Friends,

It is with great pleasure that we invite you, on behalf of the Swiss Transplantation Society, to join us at the 23rd Annual Congress on January 22 and 23, 2026 at the Congress Hotel Seepark, in Thun.

We believe that our scientific committee has once more prepared an attractive program, trying to focus on relevant issues, both for transplant patients and for transplant specialists. In addition, based on the success in encouraging a new generation during the last meeting in 2025, we are confident that also this year many younger investigators will submit their work. The rapid-fire session is the perfect platform to show their own research and to compete for the award, dedicated to young academic colleagues. We are very thankful to our sponsors who made this possible.

Among the meeting topics, we would like to highlight two: First, the **patient advisory board** of the Swiss Transplant Cohort Study will highlight its role and the growing importance of patient involvement in research. Secondly, the **key note presentation** by Serena MacMillan, from Cambridge UK; will be about "Correcting ABO incompatibility by enzymatic cleavage", an new concept which could have major implication for transplantation.

Lastly, the meeting is also about coming together and foster the exchange between different programs, and between disciplines and professions.

We would like to thank therefore all our sponsors for their very essential participation and our colleagues at meeting.com for their faithful, efficient and friendly support. The Board of our Society and the Scientific Committee are very much looking forward to seeing you soon in Thun and wish you all a very pleasant and fruitful congress.

Philipp Dutkowski
President STS

Nicolas Mueller
Chair, Scientific Committee 2025

General information

Venue

Congress Hotel Seepark
Seestrasse 47, 3602 Thun – www.seepark.ch
T +41 (0)33 226 12 12 – info@seepark.ch

Congress Office

Office Secretariat STS – meeting.com Congress Organisation
Rue des Pâquis 1 – CP 100 – 1033 Cheseaux-sur-Lausanne
T +41 (0)21 312 92 61 – info@meetingcom.ch



Registration fees

	Early bird Until Dec. 15, 2025	Late As from Jan. 19, 2025 and onsite
Medical doctors/participants STS MEMBER	CHF 230.00	CHF 270.00
Medical doctors/ JUNIOR < 35 years STS MEMBER	CHF 190.00	CHF 230.00
Medical doctors/ JUNIOR < 35 years STS NON-MEMBER	CHF 220.00	CHF 250.00
Medical doctors/participants STS NON-MEMBER	CHF 360.00	CHF 390.00
Transplant care specialists & TPL coordinators STS MEMBER	CHF 160.00	CHF 200.00
Transplant care specialists & TPL coordinators STS NON-MEMBER	CHF 240.00	CHF 260.00
ABSTRACT Presenters	CHF 0.00	CHF 0.00

Networking dinner – Thursday January 22, 2026

Participation costs 1 person	CHF 120.00 (TTC)
2 persons	CHF 240.00 (TTC)

Including

Attendance at the scientific sessions and exhibition area, certificate of participation, coffee breaks and lunches according to the program. The networking dinner is not included and has to be booked separately.

Awards for Young Clinicians or Investigators

Once again in 2026, the Scientific Committee wishes to give young fellows a voice by renewing, for the second time, the oral and poster presentations of the work they carried out during 2025.

The oral and poster presentations are dedicated to “young investigators” (medical doctors, nurses, allied health professionals). In order to be chosen as a presenter of a short report or poster, the first author must fulfil all of the following criteria:

- a maximum of 10 years of clinical experience from passing the final medical exams or master/PhD in nursing science
- first author is not the head of a research group;
- first author is not an established university lecturer (i.e., not “Privatdozent”, novenia legendi) or professor in nursing research.

The 10 highest scoring abstracts will be presented as oral presentations on Friday January 23, 2026. The additional submissions will have the possibility to present their work during a dedicated poster walk during the lunch break on Friday.

The committee would like to reward the best oral presentation and the best poster with a prize of CHF 750.00 each, for a total of CHF 1,500.00.

These awards are kindly supported by



Abstract Book

QR will be available in due time.

Thursday, January 22, 2026

09.30 – 12.00	Swiss Transplant Working Group Meetings (to be registered separately)	
13.00 – 13.05	Welcome <i>Philipp Dutkowski, Basel</i> <i>President of the Swiss Transplantation Society</i>	Room Genève
13.05 – 13.25	Swiss Transplant Annual Activity Report <i>Franz Immer, Franziska Beyeler, Swiss Transplant, Bern</i>	
13.25 – 13.45	Patient Advisory Board presentation Combining different perspectives – patient involvement in research <i>Patient Advisory Board of the STCS</i>	

13.45 – 14.30	Session 1 SPONSORED SYMPOSIUM by OM Pharma From Liver to Kidney: Innovations in Transplantation and CKD prevention Chair: Julien Vionnet, Lausanne	Room Genève 
13.45 – 13.50	Introduction of the topic and goal of the session <i>Julien Vionnet, Lausanne</i>	
13.50 – 14.05	Determinants and impact of chronic kidney disease after liver transplantation <i>Daniel Sidler, Bern</i>	
14.05 – 14.25	Learning from the MOTTO Study <i>Caroline den Hoed, Rotterdam (NL)</i>	
14.25 – 14.30	Closing remarks <i>Julien Vionnet, Lausanne</i>	

14.30 – 16.00	Session 2 COORDINATOR'S CORNER (program with SDTA) Chairs: Isabelle Binet, St. Gallen; Mirjam Korner, Bern	Room Genève
14.30 – 14.50	Liver Allocation for children <i>Barbara Wildhaber, Geneva</i>	
14.50 – 15.10	The impact of artificial intelligence and machine learning in organ retrieval and transplantation: A comprehensive review <i>David B. Olawade, London (UK)</i>	
15.10 – 15.15	Discussion <i>Isabelle Binet, St. Gallen; Mirjam Korner, Bern</i>	

Thursday, January 22, 2026

15.15 – 15.35	Basel experience of pediatric Kidney transplant in adult <i>Stefan Schaub, Basel</i>	
15.35 – 15.55	Long-term outcome following pediatric kidney transplantation is similar to adult kidney transplantation <i>Andras Meszaros, Innsbruck (AT)</i>	
15.55 – 16.00	Discussion <i>Isabelle Binet, St. Gallen; Mirjam Korner, Bern</i>	

16.00 – 16.30	Coffee break – visit of the exhibition	Foyer 1st floor
----------------------	---	-----------------

16.30 – 17.15	Session 3 SPONSORED SYMPOSIUM by Neovii Chair: tbc	Room Genève 
16.30 – 17.05	Use and dosage of ATLG/Grafalon in allogeneic HSCT: Is risk-adapted individualization possible and advisable? <i>Johannes Clausen, Linz (DE)</i>	
17.05 – 17.15	Discussion	

17.15 – 18.15	Session 4 STS AWARDS Oral presentation of the six highest ranking papers Chair: Patricia Hirt, Basel	Room Genève    
17.15 – 17.25	Paper 1	
17.25 – 17.35	Paper 2	
17.35 – 17.45	Paper 3	
17.45 – 17.55	Paper 4	
17.55 – 18.05	Paper 5	
18.05 – 18.15	Paper 6	

18.15 – 18.45	GENERAL ASSEMBLY	Room Genève
----------------------	-------------------------	-------------

19.30	Networking Dinner & STS Awards	Parksaal Hotel Seepark
--------------	---	------------------------

Friday, January 23, 2026

07.45 – 08.30

Registration

08.30 – 09.00

Keynote Lecture

Chair: Déla Golshayan, Lausanne

Room Genève

08.30 – 09.00

Correcting ABO incompatibility by enzymatic cleavage

Serena MacMillan, Cambridge (UK)

09.00 – 10.10

Session 5

Rapid Fire Session

Chair: Jean Villard, Geneva

Room Genève

09.00 – 09.06
S01

01

09.07 – 09.13
S02

02

09.14 – 09.20
S03

03

09.21 – 09.27
S04

04

09.28 – 09.34
S05

05

09.35 – 09.41
S06

06

09.42 – 09.48
S07

07

09.49 – 09.55
S08

08

09.56 – 10.02
S09

09

10.03 – 10.09
S10

010

10.10 – 10.45

Coffee break – visit of the exhibition

Foyer 1st floor

Friday, January 23, 2026

10.45 – 11.40	SPONSORED SYMPOSIUM BY ASTELLAS	Room Genève
	Immunosuppression Chair: Nicolas Müller, Zurich	
10.45 – 11.05	Enhancing Patient Adherence for Transplant Success <i>Sabina De Geest, Basel</i>	
11.05 – 11.25	AI and Machine Learning Demystified: Essential Concepts and Practical Insights <i>Valentin Goutaudier, Paris (FR)</i>	
11.25 – 11.40	Discussion	

11.40 – 12.40		ROOM Genève
Session 6	Centralisation of Machine Perfusion Chair: Pascale Tinguely, Zurich	
11.40 – 12.10	The Centralization of Organ Perfusion – UK Implementation of National Organ Assessment & Recovery Centers <i>David Nasralla, London (UK)</i>	
12.10 – 12.40	The Swiss Perspective: Status quo, Possibilities and Challenges <i>tbc</i>	

12.40 – 13.30	Lunch break – visit of the exhibition	Foyer 1st floor
13.00 – 13.30	Poster walk	

13.30 – 13.45	Presentation of the selected Honorary Member	ROOM Genève
	Chair: tbc	
13.30 – 13.35	Presentation	
13.35 – 13.45	Selected honorary member	

13.45 – 14.15	STS EXCELLENCE & INNOVATION AWARDS 2025	ROOM Genève
	with the kind support of Astellas Chair: Markus Barten, Hamburg (DE)	
13.45 – 13.55	Welcome word	
13.55 – 14.05	STS Excellence Award	
14.05 – 14.15	STS Innovation Award	

Friday, January 23, 2026

14.15 – 14.30	Best Oral & Best Poster presentation Awards	ROOM Genève
	with the kind support of Astellas Chair: Nicolas Müller, Zurich	
14.15 – 14.30	Awards	

14.30 – 16.15		Room Genève
Session 7	A case to remember Chair: Angela Koutsokera, Lausanne	
14.30 – 14.45	Primary Hyperoxaluria Typ 1 <i>Nora Pobitzer, Zurich; Wesley Hayes, Zurich</i>	
14.45 – 15.00	Kidney-alone transplantation with RNAi in PH1 <i>Alexander Ritter, St. Gallen</i>	
15.00 – 15.15	Lung transplantation <i>Pieter-Jan Gijs, Lausanne</i>	
15.15 – 15.30	Beating Heart heart transplantation and much more... current trends in ex-vivo perfusion <i>David Reineke, Bern</i>	
15.30 – 15.45	Pancreas / Islet transplantation <i>Fabian Rössler, Zurich</i>	
15.45 – 16.00	Liver transplantation <i>Massimo Leo, Geneva</i>	
16.00 – 16.15	Liver transplantation directly after HCT <i>Jonas Loetscher, Basel</i>	

16.15	Closing remarks	Room Genève
	<i>Philipp Dutkowski, Basel – President of the Swiss Transplantation Society</i>	

Committees

STS Board

Prof. Philipp Dutkowski, Basel	President
Prof. Jean Villard, Geneva	President-elect
Dr Alexander Ritter, St. Gallen	Secretary
PD Dr Patrizia Amico, Basel	Treasurer
Prof. Nicolas Müller, Zurich	Science and Research
Dr Angela Koutsokera, Lausanne	Education/ CME
Dr Federico Storni, Bern	Communication/ Website
Prof. Hendrik Tevaearai Stahel, Zurich	Past President

STS Scientific Committee Members

Amico Patrizia, Basel	Immunology & Kidney	Internal Medicine
Banz Vanessa, Bern	Liver	Internal Medicine
Drexler Beatrice, Basel	Bone marrow	Internal Medicine
Dutkowski Philipp, Zurich	Liver	Surgery
Ferrari-Lacraz Sylvie, Geneva	Immunology	Internal Medicine
Flammer Andreas, Zurich	Heart	Internal Medicine
Folie Patrick, St.Gallen	Kidney	Surgery
Golshayan Déla, Lausanne	Kidney	Internal Medicine
Haidar Fadi, Geneva	Kidney	Internal Medicine
Hirt-Minkowski Patricia, Basel	Kidney	Internal Medicine
Kremer Andreas, Zurich	Liver	Internal Medicine
Longnus Sarah, Bern	Heart	Basic Science
Müller Nicolas, Zurich	Infectious diseases	Internal Medicine
Neofytos Dionysios, Geneva	Infectious diseases	Internal Medicine
Schuermans Macé, Zurich	Lung	Thoracic Surgery
Tinguely Pascale, Zurich	Liver	Internal Medicine

For your adult and pediatric D+/R- kidney transplant recipients, CMV management is challenging to navigate¹

Begin the prophylaxis journey with PREVYMIS®

NOW INDICATED
CMV prophylaxis with PREVYMIS® for high-risk adult and pediatric D+/R- kidney transplant recipients²

PREVYMIS® helps keep your appropriate patients protected following kidney transplantation.²

Proven efficacy¹ **Good safety profile^{2,3}** **Once-daily dosing²** **Low risk of cross resistance^{2,3}**

CMV prophylaxis with PREVYMIS® should be started on day 0 of transplantation and no later than day 7 after kidney transplantation and continued until week 28 (approx. 200 days) after transplantation.³

References: 1. Kotton CN, Kumar D, Caliendo AM, et al. The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2018;102(6):900–931. doi:10.1097/TP.0000000000002191. 2. Limaye AP, Budde K, Humar A, et al. Letermovir vs valganciclovir for prophylaxis of cytomegalovirus in high-risk kidney transplant recipients: a randomized clinical trial. JAMA. 2023;330(1):33–42. doi:10.1001/jama.2023.9106. 3. Prescribing information PREVYMIS® (letermovir), www.swissmedicinfo.ch, last accessed 31.07.2025. Copies of the study publications can be requested on demand at dpoc.switzerland@msd.com.

Abbreviations: CMV: Cytomegalovirus; D+/R-: donor CMV seropositive/recipient CMV seronegative.

Short Prescribing Information PREVYMIS® (letermovir). **PREVYMIS®: At:** letermovir. **I: Adults:** prophylaxis of cytomegalovirus (CMV) infection or disease in CMV-seropositive recipients [R+] of an allogeneic haematopoietic stem cell transplant (HSCT). **D: Adults:** 480mg once daily, orally or intravenously; started no later than 28 days after HSCT; continued for up to a maximum of 200 days post-HSCT; Prevymis is available in three pharmaceutical forms: film-coated tablets, granules in sachet (orally mixed with soft food or via nasogastric or gastric tube), concentrate for solution for infusion; use the solution for infusion only when oral therapy is impossible; dilute concentrate before administration and slowly administer the entire contents i.v. over 60 minutes; i.v. infusion only using a sterile 0.2 or 0.22µm polyethersulfone (PES) inline filter; do not administer as a rapid infusion or bolus. If co-administered with cyclosporine, decrease Prevymis to 240mg once daily. **For further indications and the corresponding dosages for adults and pediatric patients, please refer to the prescribing information.** **CI:** Hypersensitivity to letermovir/exipients; concomitant administration with pimozide, ergot alkaloids, St. John's wort (*Hypericum perforatum*) or ciclosporin in combination with dabigatran, atorvastatin, simvastatin, rosuvastatin, pitavastatin. **Pr:** The safety and efficacy of letermovir has been established in patients with a negative CMV DNA test result prior to initiation of prophylaxis. CMV DNA was monitored on a weekly basis until post-transplant Week 14, and subsequently bi-weekly until Week 24. Not recommended in moderate hepatic impairment combined with moderate or severe renal impairment, severe hepatic impairment (Child Pugh C), end-stage renal disease (CrCl < 10ml/min) or dialysis patients. Risk associated with excipient hydroxypropyl betadex in intravenous formulation. Risk of adverse reactions or reduced therapeutic effect due to medicinal product interactions. **DDI:** The combination of cyclosporine and letermovir may lead to more marked or additional effects on concomitant medicinal products as compared to letermovir alone. Co-administration of PREVYMIS® with strong and moderate inducers of transporters (e.g. P-gp) and/or enzymes (e.g. UGTs) is not recommended, as it may lead to subtherapeutic letermovir exposure. Letermovir is an inhibitor of OATP1B1/3 transporters and may result in a clinically relevant increase in plasma concentrations of co-administered medicinal products that are OATP1B1/3 substrates. Co-administration of PREVYMIS® with medicinal products that are inhibitors of OATP1B1/3 transporters may result in increased letermovir plasma concentrations. Letermovir is a moderate inducer of enzymes and transporters; Induction may give rise to reduced plasma concentrations of some metabolised and transported medicinal products. Letermovir is a moderate inhibitor of CYP3A: Co-administration of PREVYMIS® may result in clinically relevant increases in the plasma concentrations of co-administered CYP3A substrates. Letermovir has the potential to decrease the exposure of CYP2C9 and/or CYP2C19 substrates potentially resulting in subtherapeutic levels. Letermovir is an inducer of intestinal P-gp: Administration of PREVYMIS® may result in a clinically relevant decrease in plasma concentrations of co-administered medicinal products that are significantly transported by P-gp in the intestine. PREVYMIS® should be used with caution when co-administered with medicinal products metabolised by CYP2B6, CYP2C8, UGT1A1 or transported by BCRP, OATP2B1 or by the renal transporter OAT3. **P/L:** Pregnancy: not recommended; do not breastfeed. **UDE:** Common: nausea, diarrhoea, vomiting. **P:** Film-coated tablets: 28 tablets of 240mg and 480mg; granules in sachet: 30 sachets with 20mg or 120mg; vial: 240mg/12ml; 480mg/24ml. **C:** A. **MAH:** MSD Merck Sharp & Dohme AG, Werftstrasse 4, Lucerne, Switzerland; (V6.0); CH-CYT-00006.

A copy of the complete product information is available at the booth of MSD Merck Sharp & Dohme AG.

Before prescribing please consult the full prescribing information published on the website of Swissmedic (www.swissmedicinfo.ch).

Copyright © 2025 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. CH-CYT-00174; created in August 2025.



MSD Merck Sharp & Dohme AG

Werftstrasse 4, CH-6005 Lucerne, Switzerland
 Phone +4158 618 30 30, Fax +4158 618 30 40
 msd.ch

Sponsors

PLATINUM



GOLD



SPONSORS

